National Health and Medical Commission: Will gradually solve the problem of insufficient HPV vaccine supply and promote free vaccination of more people

On May 30, the National Health and Health Commission held a press conference. Wang Linhong, chairman of the Women’s Health Branch of the Chinese Preventive Medicine Association and chief chronic disease expert of the China Center for Disease Control and Prevention, said that at present, five HPV vaccine products have been approved for registration in my country. , including 3 imported HPV vaccines and 2 domestic HPV vaccines. According to the data from the National Routine Immunization Statement, from 2018 to 2020, the number of HPV vaccinations increased year by year, from 3.417 million doses in 2018 to 12.279 million doses in 2020. In general, the current HPV vaccine is still in short supply, and the HPV vaccination rate of school-age women is at a low level.

Recently, the country has been actively strengthening the scientific publicity of HPV vaccination and promoting the pilot work of HPV vaccination . According to the work idea of ​​overall advancement and key breakthroughs, the three provinces of Guangdong, Hainan and Fujian have been promoted to start the implementation of free domestic bivalent HPV vaccine vaccination for school-age girls in the province, and it will be included in the 2022 provincial party committee and provincial government’s practical projects for the private sector. Many cities use the Healthy City platform to promote the pilot work of comprehensive cervical cancer prevention and control. Jinan, Xiamen, Wuxi, Ordos and other pilot cities have introduced free HPV vaccination policies for school-age girls. It can meet the different needs of clients for HPV vaccine. The recent summary data shows that the HPV vaccination rate of covered junior high school girls in these areas has greatly increased, and some cities have exceeded 90%. In the next step, the National Health Commission will vigorously summarize and promote the experience of pilot testing, and promote the free HPV vaccination policy to cover more people. At the same time, strengthen multi-departmental collaboration to gradually solve the problem of insufficient HPV vaccine supply, and strive to meet the demand for vaccination.

Wang Linhong said that currently available HPV vaccines in my country include bivalent vaccine, quadrivalent vaccine and 9-valent vaccine, which are used in women aged 9 to 45 years, but they have a high risk of cervical cancer HPV. The most important types are subtypes 16 and 18, so bivalent vaccine can prevent more than 70% of cervical cancers, which is the vast majority of cervical cancers.

She specifically pointed out that the protection effect of HPV vaccine is the best for adolescent girls who have not been infected with the virus, and the World Health Organization recommends girls aged 9 to 14 as the primary vaccination group , the earlier the vaccination, the better the effect. Therefore, in the current situation of tight supply of HPV vaccines, there is no need to miss the best vaccination time because of waiting for higher-priced vaccines.